We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Manufacturers of forthcoming biosimilars argue that their products should have the same international non-propriety name (INN) as the reference product, and do not need a unique qualifier to distinguish them from the brand version for the purposes of tracking. Read More
Generic drugmakers want the FDA to better define what qualifies for a “controlled correspondence” under a draft guidance that aims to speed agency responses to manufacturer queries. Read More
Drugmakers are split on whether the FDA should establish a program to reserve proprietary product names, with some calling for a new fee-based system and others recommending ways to improve the current process that has derailed applications with late-stage name rejections. Read More
The FDA has made progress addressing its looming ANDA backlog, assigning 65 percent of the languishing applications a targeted action date, say top agency officials, who add that new generic drug review processes will improve response rates going forward. Read More
The FDA wants to improve the way it communicates with sponsors of investigational new drug applications and is seeking industry and academia’s advice on how to accomplish that goal. Read More
Merck’s cancer drug Keytruda has received its second FDA breakthrough therapy designation, this time for advanced non-small cell lung cancer. Read More
Generic drugmakers frequently miscalculate the amount of user fees they owe the FDA, a situation that has landed many companies on the GDUFA arrears list, the head of the FDA's user fee management division said. Read More
A federal judge slashed the $9 billion jury verdict levied against Takeda and Eli Lilly to $36.8 million in a case that alleged the companies misled patients about cancer risks of the diabetes drug Actos. Read More